GlaxoSmithKline Pharmaceuticals Ltd Stock Price Today (NSE: GLAXO)
Fundamental Score
GlaxoSmithKline Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
GlaxoSmithKline Pharmaceuticals Ltd share price today is ₹2655.40, up +1.71% on NSE/BSE as of 31 July 2026. GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹42.07K (Cr). The 52-week high for GLAXO share price is ₹3198.10 and the 52-week low is ₹2088.10. At a P/E ratio of 43.73x, GLAXO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 45.61% and a debt-to-equity ratio of 0.01.
GlaxoSmithKline Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
GlaxoSmithKline Pharmaceuticals Ltd share price chart: 7.74% return over the past month. 52-week high ₹3198.10, 52-week low ₹2088.10.
GlaxoSmithKline Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2617.90 | ₹2679.00 | ₹2564.70 | ₹2655.40 | 1.18L (Cr) | |
| ₹2616.00 | ₹2639.40 | ₹2591.30 | ₹2610.70 | 68.28K (Cr) | |
| ₹2645.90 | ₹2670.00 | ₹2609.00 | ₹2626.40 | 59.54K (Cr) | |
| ₹2553.90 | ₹2669.00 | ₹2538.80 | ₹2632.60 | 1.02L (Cr) | |
| ₹2524.00 | ₹2563.80 | ₹2494.10 | ₹2551.20 | 67.92K (Cr) | |
| ₹2490.20 | ₹2525.80 | ₹2455.00 | ₹2514.30 | 63.78K (Cr) | |
| ₹2560.00 | ₹2570.00 | ₹2490.00 | ₹2495.00 | 60.97K (Cr) | |
| ₹2475.00 | ₹2510.00 | ₹2465.20 | ₹2506.60 | 41.48K (Cr) | |
| ₹2454.50 | ₹2500.00 | ₹2445.40 | ₹2483.10 | 56.88K (Cr) | |
| ₹2506.30 | ₹2510.60 | ₹2430.00 | ₹2454.80 | 56.16K (Cr) |
GlaxoSmithKline Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2476.80 | ₹2679.00 | ₹2370.00 | ₹2655.40 | +7.21% | |
| ₹2200.00 | ₹2460.90 | ₹2088.10 | ₹2450.30 | +11.38% | |
| ₹2342.00 | ₹2520.00 | ₹2194.40 | ₹2210.20 | -5.63% | |
| ₹2305.00 | ₹2529.90 | ₹2261.90 | ₹2336.40 | +1.36% | |
| ₹2520.00 | ₹2581.60 | ₹2217.60 | ₹2283.00 | -9.40% | |
| ₹2400.20 | ₹2719.80 | ₹2342.10 | ₹2571.60 | +7.14% | |
| ₹2476.00 | ₹2528.00 | ₹2220.30 | ₹2401.60 | -3.00% | |
| ₹2551.00 | ₹2635.00 | ₹2362.60 | ₹2473.60 | -3.03% | |
| ₹2644.00 | ₹2694.00 | ₹2404.20 | ₹2569.50 | -2.82% | |
| ₹2659.70 | ₹2795.90 | ₹2601.00 | ₹2618.60 | -1.55% | |
| ₹2786.00 | ₹2883.40 | ₹2622.60 | ₹2659.70 | -4.53% | |
| ₹2930.10 | ₹2936.00 | ₹2560.00 | ₹2785.00 | -4.95% |
AI Research Briefing
Powered by Gemini · 2026-04-09
GSK's expensive pivot to specialty pharma needs flawless execution to justify its premium valuation.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. GlaxoSmithKline Pharmaceuticals Ltd submitted its Q4FY26 compliance certificate to stock exchanges.
CORE STORY (THE REAL GAME)
- Focus on specialty medicines driving growth
- Strategic acquisitions bolstering pipeline
- Increased dividend signaling financial confidence
- Successful commercial launches of new specialty drugs
- Positive results from pivotal clinical trials
- Further strategic acquisitions to expand pipeline
- High P/E ratio compared to industry average
- Declining growth in general medicines
- Currency fluctuation risks
FII decreased their holdings by 0.1%, while DII increased their holdings by 0.04%. Promoter holding remains unchanged at 75.0%.
Indian pharmaceutical exports are projected to reach $130 billion by 2030, providing a tailwind for GSK's India operations.
Yes - Free Cash Flow 5Y: ₹5204.49 Cr
GSK's 3-6 month thesis hinges on successful commercial launches and positive clinical trial results. Failure to execute could lead to a significant correction.
Primary Thesis Risk
Failure to successfully transition to specialty pharmaceuticals will decimate the growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
GlaxoSmithKline Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
GlaxoSmithKline Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAXO across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (45.61%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (61.41%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (28.27%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (15.12% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.12% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (479.32x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹5538.36 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 43.73x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
GlaxoSmithKline Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare GlaxoSmithKline Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
56/100 | ₹2655.40₹2655 | ₹42072.81₹42072.81 | 43.73Average 43.7 Average | 45.61%Excellent 45.61% Excellent | 61.41%Excellent 61.41% Excellent | 0.01Excellent 0.0 Excellent | 15.12%Excellent 15.12% Excellent | 5.49%Good 5.49% Good | 2.29% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
GlaxoSmithKline Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for GLAXO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹54.76 | ₹2473.60 | 45.2x |
| FY 2024 | ₹34.83 | ₹2251.85 | 64.7x |
| FY 2023 | ₹36.05 | ₹1898.15 | 52.7x |
| FY 2022 | ₹100.04 | ₹1318.75 | 13.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
GlaxoSmithKline Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by GLAXO — dividend yield 2.29%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹749.38 Cr |
| FY 2024 | ₹541.57 Cr |
| FY 2023 | ₹1525.50 Cr |
| FY 2022 | ₹506.63 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
GlaxoSmithKline Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for GLAXO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
2.15%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
5.70%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.49%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.12%
Compounded annual net profit growth over 5 years
GlaxoSmithKline Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GLAXO — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
GlaxoSmithKline Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for GlaxoSmithKline Pharmaceuticals Ltd
About GLAXO (GlaxoSmithKline Pharmaceuticals Ltd)
GlaxoSmithKline Pharmaceuticals Ltd is a global healthcare powerhouse dedicated to the discovery, development, and manufacturing of innovative medicines and vaccines. With a legacy... spanning centuries, GSK focuses on addressing some of the world's most significant health challenges, ranging from infectious diseases and respiratory ailments to cancer and immune-related disorders. The company invests heavily in research and development, fostering a culture of scientific excellence and collaboration to accelerate the delivery of life-changing therapies. GSK's commitment extends beyond scientific innovation; it encompasses a deep-rooted dedication to ethical practices, sustainability, and improving global health equity. Through strategic partnerships and global initiatives, GSK strives to ensure that its medicines and vaccines reach those who need them most, regardless of geography or socioeconomic status. GSK's diverse product portfolio encompasses a wide range of therapeutic areas, offering solutions for prevention, treatment, and management of various medical conditions. Its vaccine division plays a crucial role in protecting individuals and communities from preventable diseases, with a strong emphasis on pediatric and adolescent immunization. From groundbreaking oncology drugs targeting specific cancer pathways to novel respiratory therapies designed to alleviate breathing difficulties, GSK's pharmaceuticals are making a tangible difference in the lives of patients worldwide. The company's commitment to innovation extends to its manufacturing processes, leveraging advanced technologies to optimize production efficiency and ensure the highest quality standards. Beyond its core business activities, GSK actively engages in corporate social responsibility initiatives, supporting programs that promote health education, access to healthcare, and community development. The company is dedicated to reducing its environmental impact and operates under stringent ethical guidelines to ensure transparency and accountability in all its operations. GSK recognizes that its success is intrinsically linked to the well-being of the communities it serves and strives to be a responsible corporate citizen, contributing to a healthier and more sustainable future. The firm’s focus is on developing and commercializing cutting-edge pharmaceutical products, which contributes to better patient outcomes.
Company Details
Key Leadership
Corporate Events
Latest News
GLAXO Share Price: Frequently Asked Questions
What is the current share price of GlaxoSmithKline Pharmaceuticals Ltd?
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) trades at ₹2655.40 on NSE and BSE. Market cap ₹42.07K (Cr). Educational data only.
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals Ltd?
GlaxoSmithKline Pharmaceuticals Ltd has a P/E of 43.73x vs industry average 34.89x.
What is the Bull Run score for GlaxoSmithKline Pharmaceuticals Ltd?
GlaxoSmithKline Pharmaceuticals Ltd has a Bull Run score of 56/100 based on 25+ financial parameters.
Does GlaxoSmithKline Pharmaceuticals Ltd pay dividends?
GlaxoSmithKline Pharmaceuticals Ltd has a dividend yield of 2.29%. Past dividends don't guarantee future payments.
What is the ROE of GlaxoSmithKline Pharmaceuticals Ltd?
GlaxoSmithKline Pharmaceuticals Ltd has ROE of 45.61%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of GlaxoSmithKline Pharmaceuticals Ltd?
GlaxoSmithKline Pharmaceuticals Ltd has debt-to-equity of 0.01.
Is GlaxoSmithKline Pharmaceuticals Ltd a good investment?
Bull Run gives GlaxoSmithKline Pharmaceuticals Ltd a score of 56/100. This is not investment advice — consult a SEBI-registered advisor.